Latest news about B·R·A·H·M·S PCT

February 2017

FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis

The U.S. Food and Drug Administration today cleared the expanded use of the Vidas Brahms PCT Assay...

Read more on FDA News Release

November 2016

Biomarkers guide safe antibiotic decisions

Overuse of antibiotics is a global problem, but the biomarker Procalcitonin (PCT), such as the B·R·A·H·M·S PCT assay from Thermo Fisher Scientific, can help guide antibiotic stewardship and reduce resistance to the effects of these drugs.

Read article in Practical Patient Care

September 26, 2016

Thermo Fisher Scientific Joins Sepsis Alliance in Support of Sepsis Awareness Month

Sepsis Awareness Month aims to provide education around a deadly condition that is claiming millions of lives globally every year.
Thermo Fisher Scientific has joined the Sepsis Alliance and advocates to spread the word about sepsis and the risk factors associated with the condition. 

Thermo Fisher Scientific Joins Sepsis Alliance in Support of Sepsis Awareness Month

July 7, 2016

Innovative trial design helps accelerate FDA clearance process for B·R·A·H·M·S PCT license partners

An innovative trial design helped our license partners, Roche Diagnostics USA and bioMérieux, achieve FDA clearance in just 90 days for the Roche ELECSYS B·R·A·H·M·S PCT and bioMérieux VIDAS B·R·A·H·M·S PCT assays. The Procalcitonin MOnitoring SEpsis Study (MOSES) included 858 adult patients with sepsis recruited across 13 investigational sites in the U.S.

B·R·A·H·M·S PCT license partners achieve FDA clearance in 90 days... > A Diagnostic Trial Designed to Speed Clearance

June 23, 2016

Roche receives FDA clearance for Elecsys B·R·A·H·M·S PCT

Roche announced that it has received 510(k) clearance for its Elecsys B·R·A·H·M·S PCT (Procalcitonin) assay as a dedicated testing solution for people with severe sepsis or septic shock. > Roche receives FDA clearance for its Procalcitonin (PCT) assay to help clinicians effectively assess sepsis risk and manage sepsis patients

March 1, 2016

Expanded FDA clearance for B·R·A·H·M·S PCT sepsis biomarker

Thermo Fisher Scientific Inc. has received clearance from the U.S. Food and Drug Administration (FDA) that expands the clinical claims of the Thermo Scientific B·R·A·H·M·S PCT (Procalcitonin) biomarker assay for sepsis risk assessment. Clinicians can now use B·R·A·H·M·S PCT to help assess the response of septic patients to treatment by comparing a baseline PCT measurement with a PCT value taken on day four.

B·R·A·H·M·S PCT cleared for assessing mortality risk of septic patients...

thermo scientific applied biosystems invitrogen fisher scientific unity lab service